Formosa Laboratories, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
November 13, 2019 at 09:39 am EST
Share
Formosa Laboratories, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced sales was TWD 789.583 million compared to TWD 684.924 million a year ago. Operating income was TWD 99.223 million compared to TWD 4.757 million a year ago. Net income was TWD 171.789 million compared to net loss of TWD 124.346 million a year ago. Basic earnings per share was TWD 1.74 compared to basic loss per share of TWD 1.28 a year ago. Diluted earnings per share was TWD 1.56 compared to diluted loss per share of TWD 1.28 a year ago. For the nine months, sales was TWD 2,037.950 million compared to TWD 1,990.605 million a year ago. Operating loss was TWD 18.574 million compared to operating Income of TWD 19.726 million a year ago. Net income was TWD 84.988 million compared to TWD 73.980 million a year ago. Basic earnings per share was TWD 0.86 compared to TWD 0.78 a year ago. Diluted earnings per share was TWD 0.82 compared to TWD 0.77 a year ago.
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.
FORMOSA LABORATORIES, INC. 
